What might a stromal response mean to prostate cancer progression?

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 411-419

  Rowley, David R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Myofibroblast; Prostate cancer; Smooth muscle; Stroma; TGF ; Wound repair

Indexed keywords

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STROMA CELL; WOUND HEALING;

EID: 0032809359     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006129420005     Document Type: Review

References (79)

1. Weiss L: In: Weiss L (ed) Cell and Tissue Biology: A Textbook of Histology. Urban & Schwarsenberg, Baltimore, 1988, pp 1-65
2. McNeal JE: Normal histology of the prostate. Am J Surg Pathol 12: 619-33, 1988
3. Shapiro H, Hartanto V, Lepor H: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 147: 1167-70, 1992
4. Shapiro E, Hartanto V, Lepor H: Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate 20: 259-67, 1992
5. Castellucci E, Prayer-Galetti T, Roclofs M, Pampinella F, Faggian L, Gardiman M, Pagano F, Sartore S: Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies. Ann NY Acad Sci 784: 496-508, 1996
6. Prins GS, Birch L: The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 136: 1303- 1314, 1995
7. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer L, Reese BA: Epithelial-mesenchymal interactions in prosate development. I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96: 1662-1670, 1983
8. Neubauer BL, Chung LWK, McCormick KA, Taguchi O, Thompson TC, Cunha GR: Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96: 1671-1676, 1983
9. Ronnov-Jessen L, Petersen OW, Bissell MJ: Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiol Rev 76: 69-125, 1996
10. Hewitt RE, Powe DG, Carter GI, Turner DR: Desmoplasia and its relevance to colorectal tumour invasion. Int J Cancer 53: 62-9, 1993
11. Lazard D, Sastre X, Frid MG, Glukhova MA, Thiery JP, Koteliansky VE: Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci USA 90: 999-1003, 1993
12. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 95: 859-73, 1995
13. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861-72, 1997
14. Thomasset N, Lochter A, Sympson CJ, Lund LR, Williams DR, Behrendtsen O, Werb Z, Bissell MJ: Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 153: 457-67, 1998
15. Lieubeau B, Garrigue L, Barbieux I, Meflah K, Gregoire M: The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 54: 6526-32, 1994
16. Owens GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75: 487-517, 1995
17. Frid MG, Shekhonin BV, Koteliansky VE, Glukhova MA: Phenotypic changes of human smooth muscle cells during development: Late expression of heavy caldesmon and calponin. Dev Biol 153: 185-193, 1992
18. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-9, 1986
19. Gregoire M, Lieubeau B: The role of fibroblasts in tumor behavior. Cancer Metast Rev 14: 339-50, 1995
20. Sieweke MH, Bissell MJ: The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog 5: 297-311, 1994
21. Anderson GR, Stoler DL, Scarcello LA: Normal fibroblasts responding to anoxia exhibit features of the malignant phenotype. J Biol Chem 264: 14885-92, 1989
22. Martins-Green M, Bissell MJ: Localization of 9E3/CEF-4 in avian tissues: expression is absent in Rous sarcoma virus- induced tumors but is stimulated by injury. J Cell Biol 110: 581-95, 1990
23. Martins-Green M, Boudreau N, Bissell MJ: Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 54: 4334-41, 1994
24. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ: Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 133: 383-9, 1998
25. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57: 673-86, 1987
26. Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87: 7235-9, 1990
27. Schmid P, Itin P, Cherry G, Bi C, Cox DA: Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 152: 485-93, 1998
28. Greenberg NN, DeMayyo F, Finegold M, Medina D, Tilley W, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443, 1995
29. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ: Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer [corrected and republished article originally printed in Lab Invest 1998 Mar; 78(3): 319-33]. Lab Invest 78: i-xv, 1998
30. Cunha GR, Chung LWK: Stromal-epithelial interactions- I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Ster Biochem 14: 1317- 1321, 1981
31. Cunha GR, Bigsby RM, Cooke PS, Sugimura Y: Stromal- epithelial interactions in adult organs. Cell Differ 17: 137- 148, 1985
32. Cunha GR, Hayward SW, Dahiya R, Foster BA: Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anatomica 155: 63-72, 1996
33. Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917-30, 1989
34. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC: Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 5: 503-13, 1991
35. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K: Genetic predisposition and mesenchymal-epithelial interactions in ras + myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7: 165-79, 1993
36. Hayashi N, Cunha GR, Wong YC: Influence of male genital tract mesenchymes on differentiation of Dunning prostatic adenocarcinoma. Cancer Res 50: 4747-4754, 1990
37. Hayashi N, Cunha GR: Mesenchyme-induced changes in neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res 51: 4924-930, 1991
38. Chung LWK, Chang S-M, Bell C, Zhau HE, Ro JY, von Eschenbach AC: Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Internat J Canc 43: 1179- 1187, 1989
39. Chung LWK: Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Canc Metas Res 10: 263-274, 1991
40. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-12, 1994
41. Robbins SE, Shu WP, Kirschenbaum A, Levine AC, Miniati DN, Liu BC: Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells. Prostate 29: 362-70, 1996
42. Chung LW: The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 23: 33-42, 1995
43. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH: Transforming growth factor B1 as a biomarker for prostate cancer. J Cel Biochem 16H: 54-61, 1992
44. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-B1 with prostate cancer. An imnumohistochemical study. Human Pathology 24: 4-9, 1993
45. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER: Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135: 2240-7, 1994
46. Gerdes MJ: Larsen M, McBride L, Dang TD, Lu B, Rowley DR: Localization of transforming growth factor- beta1 and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem 46: 379-88, 1998
47. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C: Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2: 1255- 1261, 1996
48. Williams RH, Stapleton AMF, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC: Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 2: 635-640, 1996
49. Guo Y, Jacobs SC, Kyprianou N: Down-regulation of protein and mRNA expression fur transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 71: 573-9, 1997
50. Gerdes MJ, Dang TD, Lu B, Larsen M, McBride L, Rowley DR: Androgen-regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS-1). Endocrinology 137: 864-872, 1996
51. Gerdes MJ, Dang TD, Larsen M, Rowley DR: Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139: 3569-77, 1998
52. Steiner MS, Barrack ER: Transforming growth factor-beta1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6: 15-25, 1992
53. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R: Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3: 21-30, 1997
54. Peehl DM, Cohen P, Rosenfeld RG: The insulin-like growth factor system in the prostate. World J Urol 13: 306-11, 1995
55. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81: 3774-82, 1996
56. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 81: 3783-92, 1996
57. Reubi JC, Waser B, Schaer JC, Markwalder R: Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80: 2806-14, 1995
58. Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA, Mueller C: Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 149: 501-9, 1996
59. Dalal R, Djakiew D: Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 134: 15-22, 1997
60. Hiramatsu M, Machara I, Ozaki M, Harada N, Orikasa S, Sasano H: Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 31: 118-24, 1997
61. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-96, 1995
62. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Renter VE, Nanus DM: Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 33: 225-32, 1997
63. Story MT: Regulation of prostate growth by fibroblast growth factors. World J Urol 13: 297-305, 1995
64. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKechan WL: Heparin-binding keratinocyte growth factor (FGF-7) is a candidate stromal-to-epithelial cell prostate andromedin. Molecular Endocrinology 6: 2123-2128, 1992
65. Rowley DR, Tindall DJ: Responses of NBT-II bladder carcinoma cells to conditioned medium from normal fetal urogenital sinus. Cancer Res 47: 2955-2960, 1987
66. Rowley DR: Characterization of a fetal urogenital sinus mesenchymal cell line U4F: Secretion of a negative growth regulatory activity. In Vitro Cell Dev Biol 28: 29-38, 1992
67. Rowley DR, Dang TD, Larsen M, Gerdes MJ, McBride L, Lu B: Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J Biol Chem 270: 22058-22065, 1995
68. Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR: Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type 'four-disulfide core' domain protein expressed in smooth muscle. J Biol Chem 273: 4574-84, 1998
69. Leung HY, Mehta P, Gray LB, Collins AT, Robson CM, Neal DE; Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15: 1115-20, 1997
70. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A: Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139: 4672-8, 1998
71. Jackson MW, Bentel JM, Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-8, 1997
72. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-6, 1993
73. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-25, 1998
74. Vollmer G: Expression of tenascin during carcinogenesis and involution of hormone-dependent tissues. Biochem Cell Biol 72: 505-14, 1994
75. Vollmer G, Michna H, Schneider MR: Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma. Cancer Lett 101: 185-92, 1996
76. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, Humphrey PA: Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol 24: 982-9, 1993
77. Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW, Debruyne FM, De La Rosette JJ, Schalken JA: Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol 81: 844-51, 1998
78. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ: Elevated levels of versican but not decorin predict disease progression in early- stage prostate cancer. Clin Cancer Res 4: 963-71, 1998
79. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metas 15: 246-58, 1997